Duopharma Biotech Berhad Posts Robust Q1 2020 Results with PBT of RM17.73 Million on Increased Revenue of RM158.71 Million
Higher demand from private sectors fuels improved revenue figures
Group MD remains cautiously optimistic of FY2020 financial performance